VAV3

Vav 3 oncogene
File:PBB Protein VAV3 image.jpg PDB rendering based on 2d86.
Available structures PDB Ortholog search: Template:Homologene2PDBe PDBe, Template:Homologene2uniprot RCSB List of PDB id codes 2d86​
Identifiers
Symbols	VAV3 ; FLJ40431
External IDs	Template:OMIM5 Template:MGI HomoloGene: 38143
Gene ontology Molecular function Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Cellular component Template:GNF GO Template:GNF GO Template:GNF GO Biological process Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO
RNA expression pattern
File:PBB GE VAV3 218807 at tn.png
File:PBB GE VAV3 218806 s at tn.png
More reference expression data
Orthologs
Template:GNF Ortholog box
Species	Human	Mouse
Entrez	n/a	n/a
Ensembl	n/a	n/a
UniProt	n/a	n/a
RefSeq (mRNA)	n/a	n/a
RefSeq (protein)	n/a	n/a
Location (UCSC)	n/a	n/a
PubMed search	n/a	n/a

Vav 3 oncogene, also known as VAV3, is a human gene.

This gene is a member of the VAV gene family. The VAV proteins are guanine nucleotide exchange factors (GEFs) for Rho family GTPases that activate pathways leading to actin cytoskeletal rearrangements and transcriptional alterations. This gene product acts as a GEF preferentially for RhoG, RhoA, and to a lesser extent, RAC1, and it associates maximally with the nucleotide-free states of these GTPases. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.

Further reading

• Hobert O, Schilling JW, Beckerle MC; et al. (1996). "SH3 domain-dependent interaction of the proto-oncogene product Vav with the focal contact protein zyxin". Oncogene. 12 (7): 1577–81. PMID 8622875.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Tamma SM, Chirmule N, Yagura H; et al. (1997). "CD4 cross-linking (CD4XL) induces RAS activation and tumor necrosis factor-alpha secretion in CD4+ T cells". Blood. 90 (4): 1588–93. PMID 9269777.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Trenkle T, Welsh J, Jung B; et al. (1998). "Non-stoichiometric reduced complexity probes for cDNA arrays". Nucleic Acids Res. 26 (17): 3883–91. PMID 9705494.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Movilla N, Bustelo XR (1999). "Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins". Mol. Cell. Biol. 19 (11): 7870–85. PMID 10523675.
• Trenkle T, McClelland M, Adlkofer K, Welsh J (2000). "Major transcript variants of VAV3, a new member of the VAV family of guanine nucleotide exchange factors". Gene. 245 (1): 139–49. PMID 10713454.CS1 maint: Multiple names: authors list (link)
• Zeng L, Sachdev P, Yan L; et al. (2001). "Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation". Mol. Cell. Biol. 20 (24): 9212–24. PMID 11094073.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Inabe K, Ishiai M, Scharenberg AM; et al. (2002). "Vav3 modulates B cell receptor responses by regulating phosphoinositide 3-kinase activation". J. Exp. Med. 195 (2): 189–200. PMID 11805146.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Yabana N, Shibuya M (2002). "Adaptor protein APS binds the NH2-terminal autoinhibitory domain of guanine nucleotide exchange factor Vav3 and augments its activity". Oncogene. 21 (50): 7720–9. doi:10.1038/sj.onc.1205927. PMID 12400014.
• Ota T, Suzuki Y, Nishikawa T; et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Zakaria S, Gomez TS, Savoy DN; et al. (2004). "Differential regulation of TCR-mediated gene transcription by Vav family members". J. Exp. Med. 199 (3): 429–34. doi:10.1084/jem.20031228. PMID 14757747.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Pearce AC, Senis YA, Billadeau DD; et al. (2005). "Vav1 and vav3 have critical but redundant roles in mediating platelet activation by collagen". J. Biol. Chem. 279 (52): 53955–62. doi:10.1074/jbc.M410355200. PMID 15456756.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Charvet C, Canonigo AJ, Billadeau DD, Altman A (2005). "Membrane localization and function of Vav3 in T cells depend on its association with the adapter SLP-76". J. Biol. Chem. 280 (15): 15289–99. doi:10.1074/jbc.M500275200. PMID 15708849.CS1 maint: Multiple names: authors list (link)
• Lyons LS, Burnstein KL (2006). "Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity". Mol. Endocrinol. 20 (5): 1061–72. doi:10.1210/me.2005-0346. PMID 16384856.
• Dong Z, Liu Y, Lu S; et al. (2006). "Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer". Mol. Endocrinol. 20 (10): 2315–25. doi:10.1210/me.2006-0048. PMID 16762975.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)